Theoretical Studies on Pyrazolo[3,4‐d]pyrimidine Derivatives as Potent Dual c‐Src/Abl Inhibitors Using 3D‐QSAR and Docking Approaches
Authors:
- 11 March 2014
- journal article
- research article
- Published by Wiley in Molecular Informatics
- Vol. 33 (3) , 183-200
Abstract
In recent years, the development of dual or multi‐targeted inhibitors has captured extensive attention of research for treating of malignancies. In this paper, three‐dimensional quantitative structure‐activity relationship and docking studies were performed on 87 pyrazolo[3,4‐d]pyrimidines as dual Src/Abl inhibitors. The appropriate binding orientations and conformations of these compounds interacting with both Src and Abl kinases were revealed by docking studies, and the established optimum CoMFA models yielded q2=0.856, R2=0.966 for Src and q2=0.869, R2=0.974 for Abl, and the best CoMSIA models gave q2=0.877, R2=0.979 for Src and q2=0.885, R2=0.982 for Abl. Systemic external validations further confirm the satisfactory predictive power of these models, producing R2pred values of 0.872 and 0.865 for Src, 0.876 and 0.867 for Abl, r2m values of 0.832 and 0.928 for Src, 0.838 and 0.904 for Abl, respectively. In addition, through a comparison between 3D‐QSAR contour maps and docking results, it is revealed that the hydrophobic and electrostatic interactions of compounds play significant roles for the inhibitory activity against both Src and Abl kinases. Some structural factors influencing the activities of these compounds were discussed in detail. The key amino acids impacting the receptor‐ligand interactions have been identified. These theoretical results can offer useful references for designing novel potential dual Src/Abl inhibitors.Keywords
Funding Information
- National Natural Science Foundation of China (No. 20903026)
- Natural Science Foundation of Guangdong (No. S2011010002483, S2011010002964)
- Science and Technology Planning Project of Guangzhou (No. 2013J4100071)
This publication has 44 references indexed in Scilit:
- Design, Synthesis, Biological Activity, and ADME Properties of Pyrazolo[3,4-d]pyrimidines Active in Hypoxic Human Leukemia Cells: A Lead Optimization StudyJournal of Medicinal Chemistry, 2011
- Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological dataEuropean Journal of Medicinal Chemistry, 2009
- Src as a potential therapeutic target in non-small-cell lung cancerAnnals of Oncology, 2008
- Inhibition of Bcr‐Abl Phosphorylation and Induction of Apoptosis by Pyrazolo[3,4‐d]pyrimidines in Human Leukemia CellsChemMedChem, 2007
- Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistanceProceedings of the National Academy of Sciences, 2006
- Overcoming drug resistance in chronic myeloid leukemiaCurrent Opinion in Hematology, 2006
- Discovery of N-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical AssaysJournal of Medicinal Chemistry, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Role of Src in Signal Transduction PathwaysBiochemical Society Transactions, 2002
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973